Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Oncolytics Biotech ( (TSE:ONC) ) just unveiled an update.
On July 22, 2025, Oncolytics Biotech Inc. announced it has regained compliance with Nasdaq’s minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. This compliance follows a previous notification in February 2025, where the company’s shares had fallen below the required minimum bid price. The company’s stock has now maintained a closing bid price of at least $1.00 per share for 10 consecutive business days, resolving the issue.
The most recent analyst rating on (TSE:ONC) stock is a Buy with a C$5.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the TSE:ONC Stock Forecast page.
Spark’s Take on TSE:ONC Stock
According to Spark, TipRanks’ AI Analyst, TSE:ONC is a Neutral.
Oncolytics Biotech faces significant financial challenges with persistent operational losses and reliance on external funding. Although technical indicators suggest bearish momentum, clinical advancements in cancer treatments provide some optimism. The valuation reflects the speculative nature of biotech investments, with no revenue and negative P/E. Recent earnings call and corporate events offer potential upside through strategic developments but are overshadowed by leadership transitions and market value concerns. Overall, the stock remains speculative with potential upside contingent on successful clinical outcomes.
To see Spark’s full report on TSE:ONC stock, click here.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent. The company specializes in oncology, particularly targeting metastatic breast cancer and pancreatic cancer, with its product demonstrating promising results in various clinical trials. Oncolytics is advancing towards registrational studies and has received Fast Track designation from the FDA for its efforts.
Average Trading Volume: 206,800
Technical Sentiment Signal: Buy
Current Market Cap: C$167.1M
Find detailed analytics on ONC stock on TipRanks’ Stock Analysis page.